4 Analysts Have This To Say About Exagen
In the latest quarter, 4 analysts provided ratings for Exagen (NASDAQ:XGN), showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 0 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 2 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $9.25, along with a high estimate of $10.00 and a low estimate of $8.00. A 33.93% drop is evident in the current average compared to the previous average price target of $14.00.
Investigating Analyst Ratings: An Elaborate Study
A clear picture of Exagen's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Mark Massaro | BTIG | Lowers | Buy | $9.00 | $10.00 |
| Dan Brennan | TD Cowen | Lowers | Buy | $10.00 | $13.00 |
| Mark Massaro | BTIG | Lowers | Buy | $10.00 | $15.00 |
| Anderson Schock | B. Riley Securities | Lowers | Buy | $8.00 | $18.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Exagen. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Exagen compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of Exagen's stock. This analysis reveals shifts in analysts' expectations over time.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Exagen's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Exagen analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
All You Need to Know About Exagen
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
Exagen's Economic Impact: An Analysis
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Positive Revenue Trend: Examining Exagen's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 37.87% as of 30 September, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Exagen's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -41.1%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Exagen's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -36.18%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Exagen's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -11.66%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Exagen's debt-to-equity ratio stands notably higher than the industry average, reaching 1.43. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
What Are Analyst Ratings?
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.